Acetylsalicylic morning — Competitive Intelligence Brief

Acetylsalicylic morning (Acetylsalicylic morning) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent. Area: Cardiovascular; Pain management; Inflammation.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) Cardiovascular; Pain management; Inflammation Small molecule

Target snapshot

Acetylsalicylic morning (Acetylsalicylic morning) — Basque Health Service. Acetylsalicylic acid irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to provide anti-inflammatory, analgesic, and antiplatelet effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Acetylsalicylic morning TARGET	Acetylsalicylic morning	Basque Health Service	phase 3	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Aspirin tablets	Aspirin tablets	PLx Pharma	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Ibuprofen bolus injection	Ibuprofen bolus injection	Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Rectal Indomethacin	Rectal Indomethacin	Moti Lal Nehru Medical College	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Ketorolac, intramuscular	Ketorolac, intramuscular	The University of Texas Medical Branch, Galveston	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Dexketoprofen Trometamol	Dexketoprofen Trometamol	Tokat Gaziosmanpasa University	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Aspirin First	Aspirin First	University of Pennsylvania	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent class)

1. Assistance Publique - Hôpitaux de Paris · 3 drugs in this class
2. Basque Health Service · 2 drugs in this class
3. PLx Pharma · 2 drugs in this class
4. Biogen · 1 drug in this class
5. Eli Lilly and Company · 1 drug in this class
6. Harbin Medical University · 1 drug in this class
7. Janssen Scientific Affairs, LLC · 1 drug in this class
8. Azienda Ospedaliera San Giovanni Battista · 1 drug in this class
9. Royal College of Surgeons, Ireland · 1 drug in this class
10. Shiraz University of Medical Sciences · 1 drug in this class